This year marks the 25th anniversary of the discovery of the hepatitis C virus. Since then, people with hepatitis C have had limited – and not very effective – options for treatment.
Revolutionary new treatments have hit the market in just the last few months. But they’re so expensive health insurers are balking at the price.
Part four of our series “At the Crossroads: The Rise of Hepatitis C and the Fight to Stop it” looks at the high cost of these new treatments and who’s paying for them.